CF PharmTech, Inc. (02652) disclosed a share repurchase on 12 February 2026. A total of 16,500 H shares were repurchased at prices ranging from HKD 34.76 to HKD 35.58, amounting to approximately HKD 579,920. Following the transaction, 16,500 shares were designated as treasury shares, bringing the treasury share balance to 254,500.

The total number of issued shares (excluding treasury shares) stood at 301,969,086 upon closing on 12 February 2026. The resolution authorizing the repurchase mandate was granted on 16 December 2025 for up to 30.22 million shares, with 254,500 shares repurchased since then, equivalent to 0.08% of the total number of issued shares at the time of the resolution.

The moratorium period on new share issuances or treasury share transactions is set to last until 14 March 2026. The issuer confirmed that all required procedures and regulatory protocols have been followed under the applicable listing rules.